2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Status
Terminated
4
Withdrawn
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
5
Sponsor
Cancer Type
Thoracic
5
Tumor-Agnostic
3
Gastrointestinal
3
Breast
2
Conditions
Non-small Cell Lung Cancer Metastatic
2
Stomach Neoplasms
1
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
1
Non-squamous Non-small Cell Lung Cancer
1
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
1174
Cisplatin
891
Pemetrexed
847
pembrolizumab
626
Paclitaxel
609
Docetaxel
539
Gemcitabine
428
Radiotherapy
393
Erlotinib Hydrochloride
381
Nivolumab
344
Bevacizumab
337
Etoposide
297
durvalumab
264
Drug Therapy
260
osimertinib
237
atezolizumab
225
Radiosurgery
196
Gefitinib
186
Vinorelbine
149
Magnetic Resonance Spectroscopy
132
Ipilimumab
129
130-nm albumin-bound paclitaxel
125
Cetuximab
113
Blood Specimen Collection
106
anlotinib
105
tislelizumab
103
Topotecan
103
Specimen Handling
102
Surgical Procedures, Operative
101
Cyclophosphamide
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
tusamitamab ravtansine
×
Thoracic
×
Clear all
NCT04154956
2026-05-18
CARMEN-LC03
Sanofi
Phase 3
Terminated
389 enrolled
16 charts
NCT04524689
2025-10-29
CARMEN-LC05
Sanofi
Phase 2
Terminated
57 enrolled
26 charts
NCT05245071
2025-08-29
CARMEN-LC06
Sanofi
Phase 2
Terminated
22 enrolled
11 charts
NCT04394624
2025-06-06
CARMEN-LC04
Sanofi
Phase 2
Terminated
31 enrolled
22 charts
NCT05703555
2024-02-28
INTRUSION
Erasmus Medical Center
Phase 2
Withdrawn